肥胖与胸主动脉及开窗分支腔内主动脉修复术后围手术期或临床不良结局无关
该回顾性病例对照分析纳入法国南特大学医院2016年1月至2021年12月接受胸主动脉腔内修复(TEVAR)或分支开窗腔内主动脉修复(B-FEVAR)的195例肾旁/胸腹主动脉瘤或夹层患者,按BMI≥30 kg/m²分为肥胖组52例与非肥胖组143例。两组技术成功、临床成功、总体并发症、靶血管不稳、再干预及30天和2年生存率均无统计学差异。作者指出样本量小,尚不能对肥胖作为不良事件危险因素做出结论性分析,需多中心大样本合作。
要点
- 肥胖组与非肥胖组原发技术成功(94.2% vs 94.4%,P=1.00)和临床成功(92.3% vs 95.1%,P=0.49)无统计学差异。
- 两组总体并发症(30.8% vs 21.1%,P=0.16)、30天内再干预(9.6% vs 5.6%,P=0.33)及随访期再干预(9.8% vs 20%,P=0.14)相当。
- 30天死亡率(3.8% vs 4.9%,P=1.00)和2年随访生存率(86.8% vs 78.4%,P=0.180)两组无统计学差异。
核心结论
- 在该系列中,肥胖与TEVAR/B-FEVAR术后更差的临床结局或更高死亡率无关。
- 但考虑到患者样本量小,尚不能对肥胖作为腔内治疗术后不良事件危险因素做出结论性分析;需要多中心合作的大样本才能获得确定性结论。
研究设计与样本
- 对前瞻性收集的非随机数据库进行回顾性病例对照分析,评估肥胖对B-FEVAR/TEVAR治疗肾旁/胸腹主动脉瘤和夹层术后手术及临床结局的影响。
- 研究地点为法国南特大学医院,时间范围为2016年1月至2021年12月。
- 共纳入195例患者,平均年龄69.6岁(标准差±11.2),男性135例(69.2%),平均BMI 26.6 kg/m²(范围19-41)。
- 手术类型包括TEVAR 72例(36.8%)、FEVAR 107例(55.4%)、BEVAR 14例(7.3%)。
- 按BMI分为两组:肥胖组BMI≥30 kg/m²共52例(26.7%),非肥胖组BMI<30 kg/m²共143例(73.3%)。
主要发现
- 两组仅在冠状动脉疾病(肥胖组42.3% vs 非肥胖组26.6%,P=0.035)和糖尿病(肥胖组25% vs 非肥胖组12.6%,P=0.03)上存在统计学差异。
- 原发技术成功(肥胖组94.2% vs 非肥胖组94.4%,P=1.00)和临床成功(肥胖组92.3% vs 非肥胖组95.1%,P=0.49)无统计学差异。
- 总体并发症(肥胖组30.8% vs 非肥胖组21.1%,P=0.16)、内脏血管不稳(肥胖组1.9% vs 非肥胖组1.4%,P=1.00)无统计学差异。
- 30天内再干预(肥胖组9.6% vs 非肥胖组5.6%,P=0.33)、90天内再干预(肥胖组7.7% vs 非肥胖组9.8%,P=0.78)及随访期再干预(肥胖组9.8% vs 非肥胖组20%,P=0.14)均相当。
- 30天死亡率(肥胖组3.8% vs 非肥胖组4.9%,P=1.00)和2年随访生存率(肥胖组86.8% vs 非肥胖组78.4%,P=0.180)无统计学差异。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文指出患者样本量小,尚不能对肥胖作为腔内治疗术后不良事件危险因素做出结论性分析。
- 原文指出需要多中心合作的大样本才能获得确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a risk factor for higher morbidity and mortality following open aortic repair but currently there is limited literature on its impact on clinical and procedural outcomes following thoracic endovascular aortic repair (TEVAR) and branched-fenestrated endovascular aortic repair (B-FEVAR). METHODS: We conducted a retrospective case-control analysis of a prospectively collected nonrandomized database to evaluate the effects of obesity on procedural and clinical outcomes after B-FEVAR/TEVAR in treatment of pararenal/thoracoabdominal aortic aneurysm and dissection at the University hospital of Nantes (France) between January 2016 and December 2021. Patients were divided in 2 groups according to their body mass index (BMI) and the rate of technical success, complications (renal, pulmonary, cardiac, and neurological events), 30-day and long-term survival, freedom from target vessel instability and reintervention were compared. RESULTS: 195 patients were included (mean age 69.6 DS±11.2; n = 135, 69.2% men; mean BMI: 26.6 kg/m2 range 19-41) totalling n = 72 (36.8%) TEVAR, n = 107 (55.4%) FEVAR and n = 14 (7.3%) BEVAR. Patients were divided in 2 groups [obese: BMI≥30 kg/m2n = 52 (26.7%); and nonobese, BMI<30 kg/m2, n = 143 (73.3%) that statistically differed only in terms of coronary artery disease (obese 42.3% vs. 26.6% nonobese, P = 0.035) and diabetes (obese 25% vs. 12.6% nonobese, P = 0.03). No statistical differences were noted in primary technical (94.2% vs. 94.4%, P = 1.00) and clinical (92.3% vs. 95.1%, P = 0.49) success. Overall morbidity (30.8% vs. 21.1%, P = 0.16), visceral vessels instability (1.9% vs. 1.4% P = 1.00), reintervention rate within 30 days (9.6% vs. 5.6% P = 0.33), 90 days (7.7% vs. 9.8%, P = 0.78) and during follow-up (9.8% vs. 20%, P = 0.14) were comparable. No statistical difference were noted in 30-day mortality (3.8% vs. 4.9%, P = 1.00) and the 2-year follow-up survival (86.8% vs. 78.4%, P = 0.180) between the 2 groups. CONCLUSIONS: In this series, obesity was not associated to worst clinical outcomes or higher mortality rate following TEVAR/B-FEVAR. However, considering our small patient sample, a conclusive analysis on obesity as risk factors for adverse events after endovascular treatment is not possible. A larger sample from the collaboration of multiple centers will be required to obtain definitive conclusions.
引用
- Borghese O, Quillot C, Mougin J, et al. Obesity is Not Associated with Adverse Perioperative or Poorer Clinical Outcomes following Thoracic and Fenestrated-Branched Endovascular Aortic Repair. Ann Vasc Surg. 2023. PMID: 37068628. doi:10.1016/j.avsg.2023.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。